Medicine |
Abstract Title |
Presentation Number (type), Presentation
Date, Time |
Risdiplam for spinal muscular atrophy |
FIREFISH Part 1: 1-year results on motor function in babies
with Type 1 SMA receiving risdiplam (RG7916) |
S25.003 (platform), Tuesday, 7 May, 1:22 - 1:33 p.m. EDT |
Update from SUNFISH Part 1: Safety, tolerability and PK/PD
from the dose-finding study, including exploratory efficacy data in
patients with Type 2 or 3 spinal muscular atrophy (SMA) treated
with risdiplam (RG7916) |
S25.007 (platform), Tuesday, 7 May, 2:06 - 2:17 p.m. EDT |
FIREFISH Part 1: Survival, ventilation and swallowing ability
in infants with Type 1 SMA receiving risdiplam (RG7916) |
S25.008 (platform), Tuesday, 7 May, 2:17 - 2:28 p.m. EDT |
OCREVUS (ocrelizumab) for multiple sclerosis |
Reduction in 48-Week Confirmed Disability Progression After
5.5 Years of Ocrelizumab Treatment in Patients with Primary
Progressive Multiple Sclerosis |
P3.2-031 (poster), Tuesday, 7 May, 5:30 - 6:30 p.m. EDT |
Long-Term Reduction in 48-Week Confirmed Disability
Progression After 5 Years of Ocrelizumab Treatment in Patients with
Relapsing Multiple Sclerosis |
P3.2-054 (poster), Tuesday, 7 May, 5:30 - 6:30 p.m. EDT |
Evaluation of Shorter Infusion Times with Ocrelizumab in
Patients with Relapsing-Remitting Multiple Sclerosis |
P3.2-034 (poster), Tuesday, 7 May, 5:30 - 6:30 p.m. EDT |
|
Ocrelizumab Treatment Effect on Upper Limb Function in PPMS
Patients with Disability: Subgroup Results of the ORATORIO Study to
Inform the ORATORIO-HAND Study Design |
P3.2-091 (poster), Tuesday, 7 May, 5:30 - 6:30 p.m. EDT |
Reduced Rate of Brain Atrophy in Patients with PPMS Receiving
Ocrelizumab Earlier and Continuously Versus Those Initiating
Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up |
P3.2-042 (poster), Tuesday, 7 May, 5:30 - 6:30 p.m. EDT |
FLOODLIGHT: Smartphone-Based Self-Monitoring Is Accepted by
Patients and Provides Meaningful, Continuous Digital Outcomes
Augmenting Conventional In-Clinic Multiple Sclerosis Measures |
P3.2-024 (poster), Tuesday, 7 May, 5:30 - 6:30 p.m. EDT |
Pharmacokinetics, Pharmacodynamics and Exposure-Response
Analyses of Ocrelizumab in Patients with Multiple Sclerosis |
N4.001 (platform), Wednesday, May 8, 2:00 - 2:15 p.m.
EDT |
VERISMO: A Post-Marketing Safety Study to Determine the
Incidence of All Malignancies and Breast Cancer in Patients with
Multiple Sclerosis Treated with Ocrelizumab |
P4.2-043 (poster), Wednesday, 8 May, 5:30 - 6:30 p.m.
EDT |
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis
in Patients with Relapsing and Primary Progressive Multiple
Sclerosis |
P4.2-025 (poster), Wednesday, 8 May, 5:30 - 6:30 p.m.
EDT |
One-Year Interim Analysis Results of the Phase IIIb CHORDS
Study Evaluating Ocrelizumab Effectiveness and Safety in Patients
with Relapsing-Remitting Multiple Sclerosis Who Had Suboptimal
Response with Prior Disease-Modifying Treatments |
S56.007 (platform), Friday, 10 May, 2:06 - 2:17 p.m. EDT |
|
Ocrelizumab Treatment Reduced Levels of Neurofilament Light
Chain and Numbers of B cells in the Cerebrospinal Fluid of Patients
with Relapsing Multiple Sclerosis in the OBOE Study |
S56.008 (platform), Friday, 10 May, 2:17 - 2:28 p.m. EDT |
Satralizumab for Neuromyelitis Optica Spectrum Disorder |
Efficacy of Satralizumab (SA237) in Subgroups of Patients in
SAkuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On
Study in Patients with Neuromyelitis Optica Spectrum Disorder
(NMOSD) |
S43.008 (platform), Wednesday, 8 May, 4:47 - 4:58 p.m.
EDT |
RG6042 for Huntington's disease |
Preliminary Reliability and Validity of a Novel Digital
Biomarker Smartphone Application to Assess Cognitive and Motor
Symptoms in Huntington's Disease |
P1.8-042 (poster), Sunday, 5 May, 5:30 - 6:30 p.m. EDT |
|
Defining Clinically Meaningful Change on the Composite
Unified Huntington's Disease Rating Scale (cUHDRS) |
P1.8-043 (poster), Sunday, 5 May, 5:30 - 6:30 p.m. EDT |
Translational Pharmacokinetic/Pharmacodynamic (PK/PD)
Modelling Strategy to Support RG6042 Dose Selection in Huntington's
Disease |
S16.005 (platform), Monday, 6 May, 1:44 - 1:54 p.m. EDT |
Gantenerumab for Alzheimer's disease |
Consistently Large Amyloid Reductions in Patients with and
Without ARIA-E in the Gantenerumab SCarlet RoAD and Marguerite RoAD
Open-Label Extension Studies |
S9.007 (platform), Sunday, 5 May, 4:36 - 4:47 p.m. EDT |
Crenezumab for Alzheimer's disease |
Baseline Characteristics from a Phase III Trial of Crenezumab
in Early (Prodromal-to Mild) Alzheimer's Disease (CREAD) |
P4.1-002 (poster) Wednesday, 8 May, 5:30 - 6:30 p.m. EDT |
RG6206 for Duchenne muscular dystrophy |
A Phase 1b/2 Study of the Anti-Myostatin Adnectin RG6206
(BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A
72-Week Treatment Update |
P1.6-062 (poster), Sunday, 5 May, 5:30 - 6:30 p.m. EDT |